ArticleJournal of clinical medicine2024

Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation.

Steven Deitelzweig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.